The Most Favored Patient Act of 2026 mandates a five-year pilot program requiring drug manufacturers to offer Medicare and Medicaid patients prices based on the lowest costs available in comparable international markets.
Daniel Meuser
Representative
PA-9
The Most Favored Patient Act of 2026 mandates that the Center for Medicare and Medicaid Innovation test a five-year pricing model starting in 2029 to lower drug costs for Medicare and Medicaid beneficiaries. This model requires drug manufacturers to align U.S. prices with the second-lowest net prices found in a group of eight reference countries. Manufacturers may alternatively enter into agreements that include commitments to increase domestic manufacturing operations.
New 'Most Favored Patient' Bill Targets Drug Costs: Medicare and Medicaid Prices to Match International Lows by 2029
The Most Favored Patient Act of 2026 is a massive shift in how the government handles your pharmacy bill. Starting January 1, 2029, the bill requires a five-year test of a pricing model where Medicare and Medicaid wouldn't pay a penny more for a drug than the second-lowest price paid in a group of eight other countries, including Canada, France, and Japan. Essentially, if a pharmaceutical company is giving a deep discount to a patient in London or Tokyo, this bill says they have to offer that same 'most-favored-nation' price to seniors on Medicare and low-income families on Medicaid here at home.
The Global Price Match Under Section 2, the 'most-favored-nation price' is calculated using the 'applicable net price'—the actual amount paid after all those behind-the-scenes rebates and discounts are settled. For someone managing a chronic condition like diabetes or heart disease through Medicare Part D, this could mean a significant drop in out-of-pocket costs at the pharmacy counter. The bill specifically targets drugs sold in at least two of the reference countries, ensuring we aren't just looking at one-off outliers but at established global market rates. It’s like having a price-matching guarantee for your most expensive prescriptions, backed by federal law.
The 'Made in America' Trade-Off There is a strategic loophole built into the bill that could change where your medicine is actually made. The Secretary of Health and Human Services can pause these strict price caps for a company until April 1, 2029, if the manufacturer signs a 'covered agreement.' To get this hall pass, a company has to agree to the lower pricing and—here is the kicker—commit to increasing their manufacturing operations right here in the U.S. For a factory worker in the Midwest or a logistics manager in a port city, this provision isn't just about cheaper meds; it’s a direct play to bring pharmaceutical jobs back to American soil.
Potential Side Effects for the Industry While the bill is a win for the wallet, it raises some real-world hurdles. Because the pricing is tied to the second-lowest international rate, pharmaceutical companies and their investors might see a hit to their bottom line. This could lead to a 'squeezing the balloon' effect—where companies might try to hike prices in the private insurance market to make up the difference, or potentially scale back on researching the next generation of breakthrough cures. Additionally, calculating the 'net price' across eight different countries with different currencies and healthcare systems is a bureaucratic mountain to climb, leaving plenty of room for technical errors or delays in getting these lower prices to the people who need them.